An interventional study of InogenOne Rove 6 Portable Oxygen Concentrator in Nocturnal Hypoxemia, sponsored by Inogen Inc.. Completed at 1 site in United States. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-01-05.
Sponsored by Inogen Inc. · Not applicable, Interventional, and Treatment
Among 269 studies in Hypoxia with a site in United States — 37 open to participants now, 52 under way, 2 of them phase 3. Hypoxia · United States.
Among the 269 studies in Hypoxia with a site in United States, this one is the 116th largest by enrollment of the 181 interventional ones that give a count, is one of 17 that started in 2023, is one of 110 with no phase, and was the 211th registered.
1,076 studies on the registry are indexed under Hypoxia; 213 are open to participants now.
Browse Hypoxia studies →37 of the 269 studies in Hypoxia with a site in United States are open now. Recruiting first, the newest first:
University of Alabama at Birmingham · Sites in United States
Thomas Jefferson University · Sites in United States
Joseph C. Wu · Sites in United States
Zev Rymer · Sites in United States
Wayne State University · Sites in United States
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 125 Hypoxia studies recruiting now, 53 (42%) set no upper age limit and 45 (36%) stop at 75 or younger; 15 take children under 18; 33 take healthy volunteers.
This study: 40 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
269 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 41 · Phase 2 26 · Phase 3 9 · Phase 4 8
First in 1999; this study’s year is marked. 17 started in 2023.
This study's enrollment of 20 is below the median of 45 across 769 interventional studies indexed under Hypoxia.
Median enrollment 30 across the 181 interventional studies, 30 across the 87 observational. Of the 190 that completed or were terminated, 67 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
81 of 269 have an industry lead sponsor. The 10 most frequent:
Inogen Inc. is the lead sponsor of 5 studies on the registry; 1 is open to participants now.
Inogen Inc. has 1 study filed under Hypoxia — fewer than ten, so there is no comparison to draw.
17 of the studies in Hypoxia with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06417177University of Missouri-ColumbiaImpact of Early Aging and Menopause on the Vascular Responses to Hypoxia | 2026-12 |
| NCT06692400Loma Linda UniversityThe Effects of Endotracheal Suctioning on Pain and Serum Markers | 2026-12 |
| NCT07002437University of FloridaHypoxia Pathways for Early Recovery After Spinal Cord Injury | 2026-12 |
| NCT07408388Nihon KohdenPulse Oximeter Accuracy During Stable Hypoxia Plateaus | 2026-12-01 |
| NCT06040268University of Colorado, DenverAdvair HFA in Healthy and HAPE Predisposed Subjects | 2026-12-01 |
Among the 269 studies in Hypoxia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of this study is to describe the effect of the Inogen Rove 6 Portable Oxygen Concentrator on peripheral oxygen saturation in adults receiving supplemental oxygen at night and examine whether the device can adequately maintain oxygen saturation during sleep.
The study design is a prospective, single site, single arm, open label, pilot study. The aim of this study is to describe the effect of the Inogen Rove 6 Portable Oxygen Concentrator on peripheral oxygen saturation in adults receiving supplemental oxygen at night and examine whether the device can adequately maintain oxygen saturation during sleep, i.e., achieve target with initial titration setting and/or with any needed adjustments of setting.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
InogenOne Rove 6 Portable Oxygen Concentrator
Device: InogenOne Rove 6 Portable Oxygen Concentrator
overnight use of Portable Oxygen Concentrator, 6 hours minimum
Number/% of subjects that could achieve SpO2 ≥90% for >30% of sleep time
oxygen saturation (SpO2)
Time frame: 6 hours overnight
Number/% of subjects requiring increased settings and the difference between initial and maximal settings required to meet target SpO2 ≥90% for >30% of sleep time criteria
oxygen saturation (SpO2)
Time frame: 6 hours overnight
Time/% time above/below 90% target on initial setting and maximal setting
oxygen saturation (SpO2)
Time frame: 6 hours overnight
Number, duration, variability, and AUC of dips below 90% during sleep time on initial setting and maximal setting
oxygen saturation (SpO2)
Time frame: 6 hours overnight
Minimum/maximum SpO2 on initial setting and maximal setting
oxygen saturation (SpO2)
Time frame: 6 hours overnight
Plan to share: No
No publications or documents are linked to this record.
Ran from Oct 2023 to primary completion in Dec 2023, 2 months.
Of 30 industry-sponsored interventional studies with no phase under Hypoxia, half reached primary completion within 1 month of starting (the median), counting those still running; a quarter within 0 and three quarters within 6. This study's 2 months is above that.
Counting every sponsor, half of 351 studies reached it within 12 months; a quarter within 3 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Inogen Inc.